Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France

Dorine Decarreaux1,2,3,*, Marie Pouquet2,*,†, Cecile Souty2, Ana-Maria Vilcu2, Pol Prévot-Monsacre2, Toscane Fourié3, Paola Mariela Saba Villarroel3, Stephane Priet3, Hélène Blanché4, Jean-Marc Sebaoun4, Jean-François Deleuze4, Clément Turbelin2, Andréas Werner5, Fabienne Kochert5, Brigitte Grosgogeat6,7,8,9, Pascaline Rabiega10, Julien Laupie8, Nathalie Abraham10, Caroline Guerri2, Harold Noel11, Sylvie van der Werf12,13, Fabrice Carrat2,14, Thomas Hanslik2,15,16, Remi Charrel3, Xavier de Lamballerie3, Thierry Blanchon2 and Alessandra Falchi1,†*

1 Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
2 INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France; cecile.souty@iplesp.upmc.fr (C.S.); ana-maria.vilcu@iplesp.upmc.fr (A.-M.V.); pol.prevost@iplesp.upmc.fr (P.P.-M.); clement.turbelin@iplesp.upmc.fr (C.T.);
caroline.guerri@iplesp.upmc.fr (C.G.); fabrice.carrat@iplesp.upmc.fr (F.C.); thomas.hanslik@aphp.fr (T.H.);
thierry.blanchon@iplesp.upmc.fr (T.B.)
3 Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France;
toscane.fourie@gmail.com (T.F.); marielasaba@gmail.com (P.M.S.V.); stephpriet@gmail.com (S.P.);
remi.charrel@univ-amu.fr (R.C.); xavier.de-lamballerie@univ-amu.fr (X.D.L.)
4 Fondation Jean Dausset-CEPH, 75000 Paris, France; helene.blanche@fjd-ceph.org (H.B.);
jean-marc.sebaoun@fjd-ceph.org (J.-M.S.); jean-francois.deleuze@fjd-ceph.org (J.-F.D.)
5 Association Française de Pédiatrie Ambulatoire (AFPA), 69000 Orléans, France;
doeur.werner.pediatre@wanadoo.fr (A.W.); fabienne.kochert@wanadoo.fr (F.K.)
6 Faculté d’Odontologie, Université Claude Bernard Lyon 1, Université de Lyon, 69000 Lyon, France;
brigite.grosgogeat@univ-lyon1.fr
7 Laboratoire des Multimatières et Interfaces, UMR CNRS 5615, Université Claude Bernard Lyon 1,
Université de Lyon, 69000 Lyon, France
8 Réseau ReCOL, Association Dentaire Française, 75000 Paris, France; reseau.recol@gmail.com
9 Service d’Odontologie, Hospices Civils de Lyon, 69007 Lyon, France
10 IQVIA, Réseau de Pharmaciens, 75000 Paris, France; pascaline.rabiega@iqvia.com (P.R.);
nabraham@fr.imshealth.com (N.A.)
11 Infectious Diseases Division, Santé Publique France, 94410 Saint Maurice, France;
harold.noel@santepubliquefrance.fr
12 Institut Pasteur, Université Paris Cité, CNRS UMR3569, Molecular Genetics of RNA Viruses Unit,
75015 Paris, France; sylvie.van-der-fer@pasteur.fr
13 Institut Pasteur, Université Paris Cité, National Reference Center for Respiratory Viruses, 75015 Paris, France
14 Département de Santé Publique, Hôpital Saint-Antoine, APHP, 75012 Paris, France
15 Faculty of Health Sciences Simone Veil, Université de Versailles Saint-Quentin-en-Yvelines, UVSQ,
UFR de Médecine, 78000 Versailles, France
16 Service de Médecine Interne, Hôpital Ambroise Paré, Assistance Publique—Hôpitaux de Paris (APHP),
92100 Boulogne Billancourt, France
* Correspondence: decarreaux_d@univ-corse.fr (D.D.); marie.pouquet@iplesp.upmc.fr (M.P.);
falchi_a@univ-corse.fr (A.F.)
† These authors contributed equally to this work.

Abstract: We aimed to investigate the immunoglobulin G response and neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among primary health care workers (PHCW) in France and assess the association between the neutralizing activity and several factors, including the coronavirus disease 2019 (COVID-19) vaccination scheme. A cross-sectional survey was conducted between 10 May 2021 and 31 August 2021. Participants underwent capillary blood sampling and completed a questionnaire. Sera were tested for the presence of antibodies against the nucleocapsid (N) protein and the S-1 portion of the spike (S) protein and neutralizing antibodies.
In total, 1612 PHCW were included. The overall seroprevalences were: 23.6% (95% confidence interval (CI) 21.6–25.7%) for antibodies against the N protein, 94.7% (93.6–95.7%) for antibodies against the S protein, and 81.3% (79.4–83.2%) for neutralizing antibodies. Multivariate regression analyses showed that detection of neutralizing antibodies was significantly more likely in PHCW with previous SARS-CoV-2 infection than in those with no such history among the unvaccinated (odds ratio (OR) 16.57, 95% CI 5.96–59.36) and those vaccinated with one vaccine dose (OR 41.66, 95% CI 16.05–120.78). Among PHCW vaccinated with two vaccine doses, the detection of neutralizing antibodies was not significantly associated with previous SARS-CoV-2 infection (OR 1.31, 95% CI 0.86–2.07), but was more likely in those that received their second vaccine dose within the three months before study entry than in those vaccinated more than three months earlier (OR 5.28, 95% CI 3.51–8.23). This study highlights that previous SARS-CoV-2 infection and the time since vaccination should be considered when planning booster doses and the design of COVID-19 vaccine strategies.

**Keywords:** seroprevalence; SARS-CoV-2 antibodies; neutralizing antibodies; primary care; health care workers

1. **Introduction**

Since the identification of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as the etiological agent of coronavirus disease 2019 (COVID-19), efforts have been made worldwide to prevent infection and disease [1–4]. Since December 2020, highly effective vaccines that offer high levels of protection against severe disease have been introduced worldwide. However, they do not confer mucosal immunity preventing virus entry into the respiratory tract [1–4]. In France, national vaccination campaigns were rapidly implemented at the end of 2020 to limit hospitalizations, severe consequences, and deaths due to COVID-19 [5,6]. The initial campaign phase targeted populations at risk of severe COVID-19, but it was also rapidly implemented for health care workers (HCWs) aged > 50 years on 2 January 2021, and then for all voluntary HCWs on 6 February 2021. The vaccination schedule consisted of two vaccine doses, except for the vaccination of people who had recovered from COVID-19 within 6 months before vaccination [5,6]. When mostly mild cases of breakthrough infection were reported in different countries, there was a concern that individuals in whom the immune response to the standard vaccination schedule rapidly waned could become seriously ill if infected [7–9]. The waning of vaccine-induced immunity over time and a possible increased immune evasion by the SARS-CoV-2 variants led many countries, including France, to plan the administration of a booster dose of the COVID-19 vaccine from September 2021 [5,10]. The first variants of concern (VOCs) appeared at the end of 2020. The Alpha variant spread rapidly in France after its introduction at the end of 2020 and became the majority variant in March 2021. The Beta and Gamma variants also circulated in the first half of 2021, although to a lesser extent. The Delta variant appeared in May 2021 and rapidly replaced the previous variants, becoming the major variant in France in July 2021 and represented more than 99% of the circulating variants from August 2021 [11].

More than two years after the beginning of the pandemic, the main priority of the scientific community remains the evaluation of the immunogenicity of the vaccines. Field data on vaccine immunogenicity are important for monitoring the performance of COVID-19 vaccination programs and for the planning of public health policy decisions. Various antigens have been studied for this purpose, but the nucleocapsid (N) protein and spike (S) protein are the most widely studied SARS-CoV-2 antigens. A proportion of the spike-binding antibodies are likely to have neutralizing activity. Thus, numerous studies have shown a correlation between S protein binding assays and various forms of functional virus neutralization assays [12]. Although it has been suggested that neutralizing antibodies are likely to be highly important for efficient protection against reinfection and could serve as a correlate for vaccine protection against SARS-CoV-2 in humans [13], few studies have relied on neutralizing antibodies [14].
Primary health care workers are at risk of COVID-19 through work and community exposure as well as being potential transmission sources of nosocomial infection for patients and co-workers [15]. Thus, six months after the COVID-19 vaccination campaign was launched, we conducted a French nationwide cross-sectional survey to investigate the immunoglobulin (Ig) G response and neutralizing activity in a sample of primary HCW (PHCW) populations to evaluate the titer and duration of antibody responses elicited by each vaccination scheme. For this purpose, we considered the number of COVID-19 doses received, previous SARS-CoV-2 infection, demographic factors, and the time since vaccination for the vaccinees.

2. Materials and Methods

2.1. Study Design, Time Frame, and Population

We conducted a cross-sectional study between 10 May 2021 and 31 August 2021, among the following four PHCW populations throughout metropolitan France: general practitioners (GPs), pediatricians, pharmacists and assistants, and dentists and assistants. In France, HCWs aged >50 years were eligible for COVID-19 vaccination from 4 January 2021, and all of them, regardless of age, became eligible on February 5, 2021 [16]. At the time of the survey, the third COVID-19 wave in France had ended (March 2021–May 2021). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cross-sectional studies.

2.2. Participant Sampling

The protocol study has been described in detail elsewhere [16]. Briefly, the PHCWs were recruited from the following four primary care research and monitoring networks: the French Sentinelles Network (GPs), the French Association of Ambulatory Pediatrics (pediatricians), the ReCOL network (dentists and assistants), and IQVIA (pharmacists and assistants). The PHCWs were invited by each network to enroll in the study via e-mail communication, virtual meetings, and announcements on the social media platforms for each network. All PHCWs were eligible to participate, except for those who had participated in a chemoprophylaxis clinical trial of SARS-CoV-2 infection. Participation was voluntary, and the participants registered online. Electronic informed consent was obtained from each participant before their enrolment in the study.

2.3. Data Collection and Sample Preparation

Data collection included capillary blood sampling and a questionnaire. Collection kits were mailed to each participant for at-home sample collection, including a dried blood spot (DBS) card, lancets, a pad, detailed printed instructions for performing the blood sampling, and a prepaid envelope. Returned DBSs were received at a centralized biobank (CEPH Biobank, Paris, France), and blood spots were visually assessed, registered, and punched in 2D FluidX 96-Format 0.5-mL tubes (Brooks, Chelmsford, MA, USA). Tubes containing the punches were stored before shipment at room temperature and were sent to a virology laboratory (Unité des Virus Emergents, Marseille, France) for serological analysis.

At the time of specimen collection (from May to August 2021), the PHCWs were also asked to complete a computer-based questionnaire about demographic characteristics, occupation, and clinical information, including the history since January 2020 of SARS-CoV-2 infection and COVID-19 vaccination.

2.4. Laboratory Analysis

Four chads from each dried blood spot were diluted in 380 μL PBS with 1% of penicillin/streptomycin using EpMotion 96 in fluidX micro tubes. The tubes were shaken in 96 well plates at 1050 rpm for 30 min followed by centrifugation at 4500×g for 10 min. The volume of PBS, which was decided after obtaining correspondence results for more than 1000 serum and dried blood spots, corresponds to a titration of 40. Moreover, before performing the ELISA, the hemoglobin levels in the blood spots were quantified to evaluate
the quality of the serum obtained from each blood spot. The threshold median hemoglobin level was decided after more than 1000 samples were tested beforehand. The ELISA and virus-neutralizing tests were performed using sera obtained from blood spots.

All samples were tested for antibodies against the N protein (NTD and CTD domains) and the S-1 portion of the S protein as well as neutralizing activity against SARS-CoV-2. The NTD and CTD domains of the SARS-CoV-2 N proteins used in the Luminex assay were available at the European Viral Archive goes global (EVAg) repository (www.european-virus-archive.com (accessed on 14 February 2022), ref: 100P-03956 and 100P-03957). Optimal antigen quantities and sample dilutions were selected based on the highest signal-to-noise ratio, most reproducible results, and economical use of antigen stocks. Each antigen (60 pmol/106 beads) was coupled to a separate region of MAGPLEX® magnetic microspheres (Luminex Corporation, MV’s-Hertogenbosch, the Netherlands) using the xMAP® Antibody Coupling Kit (Luminex Corporation, MV’s-Hertogenbosch, The Netherlands) following manufacturer’s recommendations. Samples diluted 1/400 in Wash Solution (Thermo Fisher Scientific, Waltham, MA, USA) were incubated with 1000 coupled beads for each antigen per well for 1 h at room temperature in a light-protected plate shaker. After washing, the beads were incubated with R-Phycocerythrin AffiniPure F(ab')2 Fragment Goat Anti-Human IgG (H + L) (Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at room temperature in a light-protected plate shaker. After washing, antigen-antibody reactions were read on a MAGPIX® system using xPONENT® Software (Luminex Corporation, MV’s-Hertogenbosch, the Netherlands) and the results were expressed as median fluorescence intensity (MFI). Using a panel of 486 plasma donors tested with commercial Anti-SARS-CoV-2 Spike S1-domain and -SARS-CoV-2 NCP IgG ELISAs from Euroimmun and a virus neutralization test in order to determine their serological status against SARS-CoV-2, the cut-off values and assay performance indicators were calculated by receiver operating characteristic curve (ROC) analysis. The specificity/sensitivity values for the CTD and NTD domains in the duplex assay were 96.1%/97.8% and 87.8%/88.5%, respectively.

A second test was performed to detect IgG antibodies against the S portion. According to the manufacturer’s (EUROIMMUN, Lübeck, Germany) instructions, a test was considered ELISA-S-positive when the results indicated an optical density ratio ≥ 1.1 (sensitivity, 87%; specificity, 97.5%) [17]. Antibody levels for ELISA-S were assigned an arbitrary binding unit (BAU) to allow comparison with other studies, as recommended by the seventy-fourth report (WHO TRS N°1039) of the WHO Expert Committee on Biological Standardization.

Finally, an in-house virus neutralization test (VNT) was used to detect neutralizing anti-SARS-CoV-2 antibodies [18]. Vero E6 cells were cultured in 96-well microplates with 100 50% tissue culture infective doses of the SARS-CoV-2 ancestral strain BavPat1 (courtesy of Prof. Drosten, Berlin, Germany) and serial dilutions of each serum sample (1/10–1/10,240). Dilutions associated with a cytopathic effect were considered negative (no neutralization), and those with no such effect at day 4 post-infection were considered positive (complete neutralization). The neutralization titer was defined as the highest dilution of serum that still yielded neutralization. Specimens with a VNT titer ≥ 20 were considered positive with a specificity of 100%. The participants received their serology test results by mail or e-mail.

2.5. Outcomes

The main outcome of this study was the presence of SARS-CoV-2 neutralizing antibodies defined as a titer ≥ 20. The secondary outcome measures were defined as the following: (i) a positive ELISA-S test, (ii) a positive ELISA-N test.

2.6. Variable Definitions

During the study period, the primary COVID-19 vaccination consisted of two vaccine doses, except for the vaccination of people who had recovered from COVID-19 within 6 months before vaccination [5,6]. Three doses were recommended for frail adults in August 2021 [19].
Participants were grouped into four different categories based on vaccination status and then self-reported biologically confirmed SARS-CoV-2 infection since January 2020. Not vaccinated participants represent participants who did not receive any doses of a COVID-19 vaccine. Vaccinated participants were grouped according to the number of COVID-19 vaccine doses (either one, two, or three doses).

A self-reported confirmed SARS-CoV-2 infection was defined as having a positive SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction (RT-qPCR), antigenic test, and/or enzyme-linked immunosorbent assay (ELISA) test result (before the first vaccine dose for vaccinees) since January 2020. Self-reported SARS-CoV-2 testing history was assessed using the following question: “Since January 2020, have you ever tested positive for a SARS-CoV-2 infection (RT-qPCR and/or antigenic test)?” (Responses: “Yes”, “No”, “Don’t Know”). This variable is cited in the text as “self-reported SARS-CoV-2 infection”. Historical strain was defined as having reported a confirmed SARS-CoV-2 infection before 31 December 2020, consistent with the virus circulation in France [11].

A previous SARS-CoV-2 infection was defined as a self-reported SARS-CoV-2 infection (as previously defined) and/or yielding a positive ELISA-N test result for the sera analyzed in this study. The variable “previous SARS-CoV-2 infection” has been used in the univariate and multivariate analysis (see §Statistical analysis).

Participants who reported a biologically confirmed SARS-CoV-2 infection more than twenty-one days after a complete primo-vaccination schedule were considered post-vaccination infected in concordance with recommendations. A complete primo-vaccination schedule was defined as having received two doses or one dose at least three months after a biologically confirmed SARS-CoV-2 infection in accordance with recommendations in France [5].

2.7. Statistical Analysis

The minimum sample size was initially calculated assuming the following: an a priori 10% seroprevalence of anti-SARS-CoV-2 IgG acquired by natural immunity (ELISA-S+ and ELISA-N+) among participants in each PHCW subpopulation, a confidence in the estimate of 95%, a maximum allowable error in the prevalence of 3%, and a minimum 20% dropout rate. Details regarding this aspect have been described elsewhere [16]. For the descriptive analysis, we selected all consenting participants who provided a serology test and returned the DBS before 31 August 2021, had interpretable serology results, and had completed the questionnaire. Standard descriptive statistics were used to present the sociodemographic and clinical characteristics of the participants. Categorical data are presented as counts and percentages. Data on continuous variables are presented as the median and inter-quartile range (IQR).

Seropositivity of neutralizing and IgG antibodies against the SARS-CoV-2 N (ELISA-N) and S (ELISA-S) proteins and their 95% confidence intervals (CIs) were estimated for all PHCWs. The seropositivity in each assay was calculated using the rate of the number of participants with a positive antibody test as the numerator and the number of participants as the denominator. Seropositivity was also presented according to the number of doses received and the presence or absence of self-reported SARS-CoV-2 infection. To calculate the 95% confidence interval for seroprevalence, we used a normal approximation interval except for samples with a seroprevalence < 5% or >95% or for a sample size < 30, when the Clopper Pearson exact method based on binomial distribution was used [20]. ELISA-S titers (BAU/mL) showed a skewed distribution and were log transformed. Log-transformed antibody levels were compared using Student’s t test and analysis of variance between groups defined by the following: (i) number of COVID-19 vaccine doses (zero, one, or two); (ii) the presence or absence of self-reported SARS-CoV-2 infection; (iii) time since the last COVID-19 vaccination (months); (iv) age (<40 years, 40–49 years, 50–59 years, or ≥60 years. The Spearman rank test was used for the analysis of correlations between the quantitative levels of anti-SARS-CoV-2 S1 IgG and the titers of neutralizing antibodies. The results were
interpreted as negligible (<0–0.19), weak (0.2–0.39), moderate (0.40–0.69), strong (0.70–0.89), or very strong (>0.9).

To identify the factors associated with the detection of neutralizing antibodies, we used a binary logistic regression model. All the following variables with \( p \)-values < 0.2 in the univariable analysis were considered in the multivariable analysis: age, sex, presence of chronic diseases, number of vaccine doses received, and previous SARS-CoV-2 infection. A step-by-step backward elimination procedure was used to identify the independent covariates associated with the presence of neutralizing antibodies in the multivariable analysis (\( p \)-value level of 0.05). To explore whether the association between the detection of neutralizing antibodies and a previous SARS-CoV-2 infection might differ according to the number of vaccine doses received, the interaction between the number of vaccine doses and previous SARS-CoV-2 infection was explored for effect modification. To evaluate the potential association between the time since vaccination and the presence of neutralizing antibodies, the variable of time since the last vaccination (in months) was also tested in models among the PHCW who received one dose and those who received two doses. Individuals with missing data for covariates considered in the regression models were excluded from the analysis. All statistical analyses were conducted using R software, version 4.0.3 (R Foundation, Vienna, Austria) [21]. Statistical significance was set at \( p < 0.05 \).

2.8. Ethics

This work was approved by the “CPP Île de France V” ethics committee (ID RCB: 2020-A03298-31). Written informed consent was obtained from all participants.

3. Results

3.1. Characteristics of Study Participants

From June 2021 to August 2021, a total of 1612 PHCWs (527 GPs, 430 pediatricians, 381 dentists and assistants, and 274 pharmacists and assistants) who completed a questionnaire and had an interpretable serological analysis were included in this study. A flow chart of the PHCW participants is shown in Figure 1.

The majority of participants were women (69%; \( n = 1112 \)) and the median participant age was 47 (range, 21–79) years (Table 1).

Table 1. Sociodemographic and clinical characteristics of the PHCWs (\( N = 1612 \); COVID-SéroPRIM study, France, 2021).

| Variable                     | Total (\( N = 1612 \)) |
|------------------------------|------------------------|
| Median age (min–max)         | 47 (21–79)             |
| Age group (years)            |                        |
| <40                          | 430 26.7                |
| 40–49                        | 460 28.5                |
| 50–59                        | 420 26.1                |
| ≥60                         | 302 18.7                |
| Sex                          |                        |
| Female                      | 1112 69.0              |
| Geographical area            |                        |
| Ile de France                | 297 18.4               |
| Northeast                    | 387 24.0               |
| Southeast                    | 362 22.5               |
| Northwest                    | 304 18.9               |
| Southwest                    | 262 16.3               |
| Occupation                   |                        |
| GP                           | 527 32.7               |
| Pediatric                    | 430 26.7               |
| Dentist                      | 331 20.5               |
Table 1. Cont.

| Variable | Total (N = 1612) |
|----------|------------------|
|          | n | % |
| Dental assistant | 50 | 3.1 |
| Pharmacist | 238 | 14.8 |
| Pharmacist assistant | 36 | 2.2 |
| **Chronic disease** | | |
| Yes | 309 | 19.2 |
| **Self-reported SARS-CoV-2 infection confirmed biologically** * since January 2020 | | |
| RT-qPCR and/or antigenic confirmed | 253 | 15.7 |
| **Symptomatic infection** ¥¥ | | |
| Yes | 191 | 75.5 |
| **Historical strain** ¥ | | |
| Yes | 138 | 72.3 |
| **ELISA confirmed** | | |
| Yes | 62 | 3.8 |
| **SARS-CoV-2 infection ≤6 months** ¥¥ | | |
| Yes | 126 | 50.2 |
| **COVID-19 vaccination and/or reported SARS-CoV-2 infection** * (N = 1604) | | |
| Not vaccinated | 124 | 7.8 |
| No self-reported SARS-CoV-2 infection | 62 | 3.9 |
| Self-reported SARS-CoV-2 infection | 62 | 3.9 |
| **One vaccine dose** | | |
| Yes | 186 | 11.6 |
| No self-reported SARS-CoV-2 infection | 45 | 2.8 |
| Self-reported SARS-CoV-2 infection | 141 | 8.8 |
| **Two vaccine doses** | | |
| Yes | 1292 | 80.5 |
| No self-reported SARS-CoV-2 infection | 1244 | 77.6 |
| Self-reported SARS-CoV-2 infection | 48 | 3.0 |
| **Three vaccine doses without self-reported SARS-CoV-2 infection** ** | | |
| Yes | 2 | 0.1 |

* Self-reported SARS-CoV-2 infection was defined as a positive RT-qPCR or antigenic and/or ELISA test declared by the participants since January 2020. ¥ Historical strain was defined as being tested RT-qPCR positive before 31 December 2020, consistent with the virus circulation in France. ¥¥ Information available for 251 participants. ¥¥¥ Information available for 190 participants. ** Participants who received three vaccine doses were considered immunocompromised, in accordance with the COVID-19 vaccination recommendations at the time of the survey.

Approximately 19.2% (n = 309) of the participants had a chronic disease. Of the 1612 participants, 15.7% (n = 253) self-reported a SARS-CoV-2 infection. Among the 191 PHCWs who reported a positive RT-qPCR and/or antigenic result, 185 (94.4%) declared having at least one symptom at the time of the diagnostic test. Regarding the COVID-19 vaccination schedule (vaccine doses and/or self-reported SARS-CoV-2 infection) of the 1604 PHCWs for whom the information was available, 80.5% (n = 1292) had received two vaccine doses, 11.6% (n = 186) one vaccine dose, and 0.1% (n = 2) three vaccine doses, whereas 7.8% (n = 124) declared that they had not been vaccinated (Table 1). Among the 1480 PHCWs who received at least one vaccine dose, 87.9% (n = 1301) were vaccinated using the BNT162b2 mRNA vaccine. The details of the vaccine types received by the participants are provided in Supplementary Table S1.

3.2. Characteristics of Participants with Self-Reported SARS-CoV-2 infection after Primary COVID-19 Vaccination

Of those with a primary COVID-19 vaccination, 0.3% (n = 4 out of 1417) reported having a positive diagnostic COVID-19 test at least 21 days after being vaccinated. Their characteristics are presented in Table 2.

The median age of this group was 57 (range, 51–63) years and 75% were men (n = 3). None declared having a biologically confirmed SARS-CoV-2 infection before vaccination. All experienced a symptomatic post vaccination infection; one was positive for the α variant, one for the γ variant, and the variant had not been identified for the other two participants.

The time between the last vaccination and infection ranged from 1 to 3 months, and the time between infection and study sampling ranged from 2 to 3 months. All these participants
showed seropositivity for IgG against the SARS-CoV-2 S and N proteins. At the time of the survey, neutralizing antibodies were detected among all of them.

Figure 1. Flow chart of the primary healthcare worker (PHCW) participants enrolled from May to August 2021 (COVID-SéroPRIM study, France, 2021).
| PHCW | Age (Years) | Sex | Occupation   | Number of Doses | Vaccine Name First Vaccine Dose* Name Second Vaccine Dose | Time between Vaccination (Last Injection and Study Sampling) (_months) | Before Vaccination | After Vaccination: Variant | Time between Vaccination and Infection (Months) | Time between Infection and Study Sampling (Months) | Symptoms | Seropositivity | Neutralizing Antibodies (VNT Titer) |
|------|-------------|-----|--------------|-----------------|----------------------------------------------------------|-------------------------------------------------------------------|-------------------|----------------------------|--------------------------------------------|-----------------------------------------------|----------|---------------|-------------------------------|
| 1    | 63          | Male | GP           | 2               | BNT162b2 missing value                                   | 5                                                                 | No                | Not known                 | 2                                          | 3                                             | Rhinorrhea | Pos           | Pos                          | 1280                          |
|      |             |      |              |                 | Cough, rhinorrhea, sore throat, diarrhea, chest pain or tightness, loss of smell, sleep disorders |                      |                   |                             |                             |                                                              | Pos       | Pos           | 160                          |
| 2    | 60          | Male | Dentist      | 2               | BNT162b2 BNT162b2                                       | 4                                                                 | No                | Alpha                     | 2                                          | 2                                             | Cough, fever, rhinorrhea, sore throat, headaches, chest pain or tightness, loss of smell, loss of appetite, tiredness, muscular pains, thrills | Pos       | Pos           | 320                          |
| 3    | 51          | Male | Pediatrician  | 2               | BNT162b2 BNT162b2                                       | 5                                                                 | No                | Gamma                     | 3                                          | 2                                             | Cough, fever, tiredness, diarrhea, loss of smell, loss of taste, dyspnea while exercising, loss of appetite, muscular pains, heart rhythm disorders, dyspnea while performing activities of daily living, feeling of dizziness, loss of balance | Pos       | Pos           | 640                          |
| 4    | 54          | Female | Pediatrician | 2               | BNT162b2 BNT162b2                                       | 4                                                                 | No                | Not known                 | 1                                          | 3                                             |                      | Pos       | Pos           | 640                          |

A complete primo-vaccination schedule was defined as having received two doses or one dose at least three months after a biologically confirmed SARS-CoV-2 infection in accordance with recommendations in France [5].

Table 2. Characteristics of the PHCWs who tested positive for SARS-CoV-2 after a complete primary COVID-19 vaccination schedule (N = 4; COVID-SéroPRIM study, France, 2021).
3.3. Seroprevalence of SARS-CoV-2 Antibodies

Table 3 shows the proportion of participants with a positive ELISA result for IgG antibodies against the SARS-CoV-2 N and S proteins and positive neutralizing antibodies according to the vaccination schedule.

3.4. Seroprevalence of Antibodies against the SARS-CoV-2 N Protein

A total of 381 of the 1612 PHCWs analyzed tested positive for antibodies against the SARS-CoV-2 N protein for a prevalence rate of 23.6% (95% CI 21.6%–25.7%, Table 3). Among them, 47.2% \( (n = 180) \) had a self-reported SARS-CoV-2 infection. Among the 251 PHCWs who had a self-reported SARS-CoV-2 infection, 71.9% \( (n = 180) \) had a positive ELISA-N test, whereas among the 1353 PHCW not declaring a self-reported SARS-CoV-2 infection, 14.6% \( (n = 197) \) had a positive ELISA-N test \( (p < 0.0001) \).
Table 3. Proportion of participants with a positive ELISA result for IgG antibodies against the SARS-CoV-2 N and S proteins and positive neutralizing antibodies according to the number of vaccine doses received and the presence or absence of a self-reported SARS-CoV-2 infection, May 2021 to August 2021, \((N = 1612; \text{COVID-SéroPRIM study, France, 2021})\).

| Variable | Anti-SARS-CoV-2 N Protein Antibodies | Anti-SARS-CoV-2 S Protein Antibodies | Seroneutralization |
|----------|--------------------------------------|--------------------------------------|--------------------|
|          | \(N\) | % (95% CI) | \(N\) | % (95% CI) | \(N\) | % (95% CI) |
| Total \((N = 1612)\) | 381 | 23.6 (21.6–25.7) | 1526 | 94.7 (93.6–95.7) | 1311 | 81.3 (79.4–83.2) |
| COVID-19 vaccination and/or self-reported SARS-CoV-2 infection * \((N = 1604)\) | | | | | | |
| Not vaccinated | | | | | | |
| No self-reported SARS-CoV-2 infection \((N = 62)\) | 7 | 11.3 (3.4–19.2) | 4 | 6.5 (0.3–12.6) | 4 | 6.5 (0.3–12.6) |
| Self-reported SARS-CoV-2 infection \((N = 62)\) | 52 | 83.9 (74.7–93.0) | 49 | 79.0 (68.9–89.2) | 39 | 62.9 (50.9–74.9) |
| One vaccine dose | | | | | | |
| No self-reported SARS-CoV-2 infection \((N = 45)\) | 8 | 17.8 (6.6–28.9) | 34 | 75.6 (63.0–88.1) | 19 | 42.2 (27.8–56.7) |
| Self-reported SARS-CoV-2 infection \((N = 141)\) | 97 | 68.8 (61.1–76.4) | 139 | 98.6 (95.0–99.8) | 133 | 94.3 (90.5–98.1) |
| Two vaccine doses | | | | | | |
| No self-reported SARS-CoV-2 infection \((N = 1244)\) | 182 | 14.6 (12.7–16.6) | 1242 | 99.8 (99.4–100.0) | 1062 | 85.4 (83.4–87.3) |
| Self-reported SARS-CoV-2 infection \((N = 48)\) | 31 | 64.6 (51.1–78.1) | 48 | 100.0 (92.6–100.0) | 45 | 93.8 (86.9–100.0) |
| Three vaccine doses | | | | | | |
| No self-reported SARS-CoV-2 infection \((N = 2)\) | 0 | 0 | 2 | 100.0 (15.8–100.0) | 2 | 100.0 (15.8–100.0) |

The normal approximation interval was used to calculate the 95% confidence interval for seroprevalence, except when the Clopper Pearson exact method based on binomial distribution was used for samples with a seroprevalence < 5% or >95% or for a sample size < 30 [20].
3.5. Seroprevalence of Antibodies against the SARS-CoV-2 S Protein and Quantitative ELISA-S Results

Among the 1612 PHCWs, 1526 tested positive for antibodies against the SARS-CoV-2 S protein for a prevalence rate of 94.7% (95% CI 93.6%–95.7%) (Table 3). The seropositivity rate for antibodies against the S protein was nearly 100% among the PHCWs who had received two vaccine doses or one vaccine dose and a self-reported SARS-CoV-2 infection.

Among the 1526 PHCWs with detectable IgG antibodies against the S protein, the mean antibody level was 1168.81 BAU/mL. Comparisons of IgG antibody levels (BAU/mL) against the S protein with the vaccination and participant characteristics are presented in Figure 2.

![Figure 2. Cont.](image-url)
Figure 2. Antibody levels (BAU/mL) for IgG antibodies against the S protein according to (a) the number of COVID-19 vaccine doses received along with the presence or absence of self-reported SARS-CoV-2 infection among the PHCWs; (b) time since the last vaccination among vaccinees; (c) age (years) of the PHCWs, May 2021 to August 2021 (n = 1602; COVID-SéroPRIM study, France, 2021).

The line in the center of each box depicts the median; the lower and upper hinges correspond to the first and third quartiles; and the distance between the first and third quartiles corresponds to the interquartile range. Student’s t test and analysis of variance were used to assess statistically significant differences in antibody levels according to the number of vaccine doses, the presence or absence of self-reported SARS-CoV-2 infection, the time since vaccination, and age categories.

A significantly higher mean antibody level was found among the PHCWs who had a self-reported SARS-CoV-2 infection than those who did not, except for unvaccinated PHCWs (zero vaccine dose, 297.95 BAU/mL versus 58.37 BAU/mL, p = 0.1434; one vaccine dose, 2089.69 BAU/mL versus 500.87 BAU/mL, p < 0.0001; two vaccine doses, 2298.07 BAU/mL versus 1076.21 BAU/mL, p < 0.0001; Figure 2a). Among the PHCWs without a self-reported SARS-CoV-2 infection, there was no statistically significant difference in the mean antibody level for those who received one vaccine dose compared to those who did not receive the vaccine, although it was close to significance (500.87 BAU/mL versus 58.37 BAU/mL; p = 0.0779). Among the PHCWs without a self-reported SARS-CoV-2 infection, there was a higher mean antibody level for those who received two vaccine doses than those who received one vaccine dose (1076.21 BAU/mL versus 500.87 BAU/mL; p < 0.0001). Among the PHCWs with a self-reported SARS-CoV-2 infection, a significantly higher mean antibody level was observed for those who received one vaccine dose than those who did not receive the vaccine (2089.69 BAU/mL versus 297.95 BAU/mL; p < 0.0001) but the antibody levels were similar for those who received two vaccine doses compared to those who received one vaccine dose (2298.07 BAU/mL versus 2089.69 BAU/mL; p = 0.2820).

The quantitative ELISA-S results showed a decrease in antibody levels as the time since the last vaccination (p < 0.0001) or age (p < 0.0001) increased (Figure 2b,c, respectively). A significantly higher mean antibody level was observed for participants who received their last vaccine dose within the 3 months before participating in the study compared to those vaccinated more than 3 months before the study (p < 0.0001), and among those aged less than 50 years compared to those aged 50 years or more (p < 0.0001).

3.6. Seroneutralizing Antibodies and Correlation with ELISA Test

A total of 1311 PHCWs (81.3%; 95% CI 79.4–83.2%) had a positive result for the VNT (Table 3). The seropositivity rate for neutralizing antibodies against SARS-CoV-2 was >90%
for the PHCWs who received at least one vaccine dose and had a self-reported SARS-CoV-2 infection. This rate was 85.4% for those who received two vaccine doses and did not have a self-reported SARS-CoV-2 infection (n = 1062 out of 1244), 62.9% for those who were not vaccinated but had a self-reported SARS-CoV-2 infection (n = 39 out of 62), 42.2% for those who received one vaccine dose without a self-reported SARS-CoV-2 infection (n = 19 out of 45), and 6.5% for those who were not vaccinated and did not have a self-reported SARS-CoV-2 infection (n = 4 out of 62; Table 3).

As shown in Figure 3, among the 1311 participants with neutralizing antibodies, 104 (7.9%), 295 (22.5%), 294 (22.4%), 252 (19.2%), 197 (15.0%), 112 (8.5%), and 57 (4.3%) participants had VNT titers of 20, 40, 80, 160, 320, 640, and ≥1280, respectively.

![Figure 3](image_url)

**Figure 3.** Distribution of seroneutralization titers among the PHCWs, May 2021 to August 2021 (N = 1602; COVID-SéroPRIM study, France, 2021).

The anti-S protein IgG titers were moderately correlated with the neutralizing antibody titers (Spearman’s rank correlation coefficient, 0.65) that was statistically significant (p < 0.0001; Figure 4).

![Figure 4](image_url)

**Figure 4.** Boxplot of the quantitative ELISA-S results according to neutralizing antibody titers among the PHCWs (N = 1602; COVID-SéroPRIM study, France, 2021).

### 3.7. Factors Associated with the Detection of Neutralizing Antibodies

Table 4 shows the results of univariable and multivariable analyses of factors associated with the detection of neutralizing antibodies among the PHCWs.
Table 4. Univariate and multivariate analyses of factors associated with the detection of neutralizing antibodies among the PHCWs according to the number of COVID-19 vaccine doses ($n = 1602$; COVID-SéroPRIM study, France, 2021).

| Variables * | $n$ (% Positive in VNT) | Univariate | Multivariate |
|-------------|-------------------------|------------|--------------|
|              |                         | Odds Ratio | 95% CI | $p$-Value | Odds Ratio | 95% CI | $p$-Value |
| Zero vaccine dose | 124                     |            |       |           |            |       |           |
| Age (years)   |                         |            |       |           |            |       |           |
| <50          | 73 (31.5)               | Reference  |       | 0.3759    |            |       |           |
| ≥50          | 51 (39.2)               | 1.40       | (0.66–2.97) | 0.9541    |            |       |           |
| Sex          |                         |            |       |           |            |       |           |
| Female       | 89 (34.8)               | Reference  |       | 0.0555    |            |       |           |
| Male         | 35 (34.5)               | 0.98       | (0.42–2.20) | 0.9541    |            |       |           |
| Chronic disease |                     |            |       |           |            |       |           |
| No           | 101 (30.7)              | Reference  |       | 0.0555    |            |       |           |
| Yes          | 13 (52.2)               | 2.46       | (0.98–6.28) | 0.0555    |            |       |           |
| Previous SARS-CoV-2 infection ** | |     |       |           |            |       |           |
| No           | 55 (92.7)               | Reference  |       | <0.0001   | Reference  |       | <0.0001   |
| Yes          | 69 (56.5)               | 16.57      | (5.96–59.36) | 16.57     | (5.96–59.36) |       |           |
| One vaccine dose | 186                     |            |       |           |            |       |           |
| Age (years)   |                         |            |       |           |            |       |           |
| <50          | 114 (81.6)              | Reference  |       | 0.9499    |            |       |           |
| ≥50          | 72 (81.9)               | 1.02       | (0.48–2.25) | 0.1879    |            |       |           |
| Sex          |                         |            |       |           |            |       |           |
| Female       | 137 (79.6)              | Reference  |       | 0.7136    |            |       |           |
| Male         | 49 (87.8)               | 1.84       | (0.75–5.20) | 0.7136    |            |       |           |
| Chronic disease |                     |            |       |           |            |       |           |
| No           | 149 (81.2)              | Reference  |       | 0.7136    |            |       |           |
| Yes          | 37 (83.8)               | 1.2        | (0.48–3.42) | 0.7136    |            |       |           |
| Previous SARS-CoV-2 infection ** | |     |       |           |            |       |           |
| No           | 35 (29.7)               | Reference  |       | <0.0001   | Reference  |       | <0.0001   |
| Yes          | 149 (94.6)              | 41.66      | (16.05–120.78) | 41.66     | (16.05–120.78) |       |           |
| Time since vaccination (months) | |     |       |           |            |       |           |
| <3           | 109 (78.9)              | 0.64       | (0.28–1.39) | 0.2641    |            |       |           |
| ≥3           | 75 (85.3)               | Reference  |       |           |            |       |           |
| Variables * | n (% Positive in VNT) | Univariate | Multivariate |
|-------------|-----------------------|------------|-------------|
|             |                       | Odds Ratio | 95% CI      | p-Value     | Odds Ratio | 95% CI      | p-Value     |
| Two vaccine doses | 1292                 |            |             |             |            |             |             |
| Age (years)   |                      |            |             |             |            |             |             |
| <50          | 701 (91.3)           | Reference  |             | <0.0001     |            |             |             |
| ≥50          | 591 (79.0)           | 0.36       | (0.26–0.50)  |             |            |             |             |
| Sex          |                      |            |             |             |            |             |             |
| Female       | 882 (87.1)           | Reference  |             |             |            |             |             |
| Male         | 410 (82.7)           | 0.71       | (0.51–0.98)  | 0.0385      |            |             |             |
| Chronic disease |                    |            |             |             |            |             |             |
| No           | 1046 (86.5)          | Reference  |             | 0.0830      |            |             |             |
| Yes          | 246 (82.1)           | 0.72       | (0.50–1.05)  |             |            |             |             |
| Previous SARS-CoV-2 infection ** |    |            |             |             |            |             |             |
| No           | 1062 (85.1)          | Reference  |             |             |            |             |             |
| Yes          | 230 (88.3)           | 1.31       | (0.86–2.07)  | 0.2082      |            |             |             |
| Time since vaccination (months) |           |            |             |             |            |             |             |
| <3           | 549 (95.1)           | 5.28       | (3.51–8.23)  | <0.0001     | 5.28       | (3.51–8.23) | <0.0001     |
| ≥3           | 737 (78.6)           | Reference  |             |             | Reference  |             |             |

* In a model including all participants, the interaction term between the number of COVID-19 vaccine doses received and the presence or absence of previous SARS-CoV-2 infection was statistically significant (p < 0.0001); thus, analyses using subgroups defined by the number of vaccine doses received were performed. ** Previous SARS-CoV-2 infection was defined as a self-reported SARS-CoV-2 infection and/or yielding ELISA-N test result achieved on the sera analyzed in this study.
Because the interaction term between the number of COVID-19 vaccine doses and the presence or absence of previous SARS-CoV-2 infection was statistically significant ($p < 0.0001$), we have presented subgroup analyses according to the number of vaccine doses. Among the participants who were not vaccinated ($n = 124$) and those who received one vaccine dose ($n = 186$), multivariable regression analyses showed that detection of neutralizing antibodies was significantly more likely in those with previous SARS-CoV-2 infection than in those with no previous SARS-CoV-2 infection (zero vaccine doses, odds ratio (OR) 16.57, 95% CI 5.96–59.36; one vaccine dose, OR 41.66, 95% CI 16.05–120.78). Among participants who received two vaccine doses ($n = 1292$), multivariate regression analyses showed that the detection of neutralizing antibodies was not significantly associated with previous SARS-CoV-2 infection (OR 1.31, 95% CI 0.86–2.07), but was more likely for those who received their second vaccine dose within the 3 months before participating in the study than those vaccinated more than 3 months before the study (OR 5.28, 95% CI 3.51–8.23). In all multivariate regression analyses, age, sex, and chronic disease were not statistically associated with the detection of neutralizing antibodies.

4. Discussion

The findings of this cross-sectional nationwide study, which included serum samples from 1612 PHCWs collected from June 2021 to August 2021, demonstrated a stronger immune response in PHCWs with a previous SARS-CoV-2 infection than those with no evidence of a previous SARS-CoV-2 infection, particularly PHCWs with a single vaccine dose. This is in line with previous studies [22–24] reporting higher and longer-lasting anti-S antibody levels among individuals with evidence of a previous SARS-CoV-2 infection than vaccinated individuals, which represents a remarkable and sustained enhancement of both the humoral and cellular responses, including higher neutralizing antibody responses [25–28]. As in previous studies [26–28], we show that PHCWs who experienced COVID-19 after a single dose of vaccine exhibited antibody titers similar to those that had received two doses of vaccine. This is in contrast with the marked antibody increase after the second dose of vaccine in PHCWs with no evidence of a previous infection before vaccination. This striking difference in antibody kinetics between previously infected and vaccinated individuals could explain the significantly lower incidence of breakthrough infection in previously infected individuals than vaccinated individuals [29–31]. In agreement with clinical trials [2] and real-world settings [32,33], we observed that PHCWs who received a two vaccine doses had higher antibody responses than unvaccinated individuals or those who received a single vaccine dose and had no reported SARS-CoV-2 infection. We found that a second vaccine dose in pre-exposed PHCWs did not increase their antibody levels, in line with previous studies [23,34]. This supports the strategy of a single-dose vaccination for PHCWs who experienced COVID-19 to achieve a primary vaccination.

Not surprisingly, given the kinetics of immune responses, the degree of protection offered by a vaccine against infection may decrease over time, allowing for more breakthrough infections as the immune response wanes over months. Notably, we identified a significant correlation between time-from-vaccine and antibody levels by reporting waning of humoral responses more than 3 months after the administration of the second vaccine dose compared to the first 3 months. This result is consistent with recent publications showing a significant decline in S-antibody levels and neutralizing antibody levels with time after the second vaccine dose [35–39]. The clinical implications for the waning of the humoral response after vaccination are therefore still unclear and it remains crucial to establish the S antibody threshold associated with protection against clinical outcomes [35–37].

In our sample, four participants who had been vaccinated declared a SARS-CoV-2 infection post vaccination. Although we cannot draw robust statistical conclusions from so few cases, it is interesting to note that none of them had a previous SARS-CoV-2 infection, and that the time between last vaccination and infection was between 1 and 3 months. Notably, these estimates were obtained at times when the $\alpha$ variant was dominant, and the estimated titers may be less effective against infection with the $\delta$ variant [40]. Determining the immune
correlates for protection against SARS-CoV-2 is necessary to predict how a decrease in antibodies will affect clinical outcomes. This will also help determine if and when a booster dose will be needed, and whether vaccinated individuals are protected from SARS-CoV-2. In line with previous studies, we found a correlation (albeit moderate) between anti-S and neutralizing antibodies [30]. An 80% vaccine efficacy against symptomatic SARS-CoV-2 infection was observed for an antibody level of 264 BAU/mL, which declined to 60% for a level of 54 BAU/mL [41]. Our findings suggest that antibody titers had declined below these threshold levels in a subgroup of the PHCWs within 3 months of the second vaccination, indicating the need for a booster. Although we did not find that antibodies waned over time in PHCWs who received one vaccine dose, vaccine recall should be considered when a long time has passed since natural infection or vaccination, because antibodies consistently decline over time. In the present study, almost one-third of the PHCWs had antibodies against the SARS-CoV-2 N protein that developed as the result of a natural SARS-CoV-2 infection. Importantly, anti-N IgG antibodies remained quite stable over a period of at least 3 months following mild or asymptomatic infection [42]. The results reported here mainly relate to the circulation of SARS-CoV-2 among the participants since December 2020 at the end of the second wave in France and at the start of the COVID-19 vaccination campaign. This finding indicates that PHCWs represent a population at considerable risk of contracting COVID-19 and highlights the relevance of vaccination for this population.

Strengths and Limitations

The main strength of this real-world study was the use of three serological tests among PHCWs, which were one of the first populations to have access to COVID-19 vaccines because of their high risk of SARS-CoV-2 exposure. Another strength was the availability of sociodemographic and clinical data. Nevertheless, our study also had several limitations. First, we did not evaluate the cellular immune response, though a correlation between cellular and humoral immunity has been reported [43]. Second, it is possible that the responders in this study may not be representative of the population as a whole, therefore limiting generalizability of our findings. In particular, the HCW sample is composed mostly of young adults, and it is important to consider the elderly in studies on immune responses, since they may have a weaker antibody response to vaccination. Third, although we measured antibodies against the N protein of SARS-CoV-2, all previous asymptomatic cases were certainly not detected given the short duration of detectable N antibodies [44]. This may lead to misclassification in pre-exposure groups. In addition, we were not able to model the antibody response according to previous symptomatic versus asymptomatic SARS-CoV-2 infection. Fourth, although we controlled for age, sex, and chronic disease, our findings might have been affected by other possible confounders that were not assessed. Fifth, we relied on self-reported results for SARS-CoV-2 infection, which may have introduced a bias in the reporting of results, leading to misclassification. Other study limitations include insufficient data to model the antibody response according to different vaccines.

5. Conclusions

Immunity due to either previous SARS-CoV-2 infection or vaccination can contribute to herd immunity and control the COVID-19 pandemic. Our study, together with others, underscores the fact that previous SARS-CoV-2 infection should be considered when planning booster doses and the design of COVID-19 vaccination strategies. Further studies should be conducted in the following months and after the booster dose to reassess seroprevalence and identify factors associated with infection among PHCWs.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/v14050957/s1, Table S1: Name of the vaccine received by the PHCWs (N = 1612; COVID-SéroPRIM study, France, 2021).
Author Contributions: Conceptualization, A.F., D.D. and M.P.; methodology, A.F., D.D., M.P., P.P.-M., S.P., C.S., A.-M.V., T.F., P.M.S.V., H.B., J.-M.S., J.-F.D., H.N., S.v.d.W., C.G., T.B., F.C., T.H., X.d.L. and R.C.; software, C.T.; validation, A.F.; formal analysis, D.D., M.P., C.S. and A.-M.V.; investigation, D.D., M.P., A.W., F.K., N.A., P.R., J.L. and B.G.; data curation, D.D., M.P. and C.S.; writing—original draft preparation, D.D., M.P. and A.F.; writing—review and editing, D.D., M.P. and A.F.; supervision, A.F.; project administration, A.F.; funding acquisition, A.F. and M.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Agence Nationale de la Recherche: ANR-20-COV5-0005-01. The CEPH-Biobank is supported by the Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation.

Institutional Review Board Statement: This study has been approved by the ethics committee “CPP Île de France V” (ID RCB: 2020-A03298-31) and the National Data Protection Agency (CNIL, registration number MLD/MAF/AR213778). The protocol described in this article is V.3 of the COVID-SéroPRIM study protocol approved on March 5 2020. Inserm is the sponsor of this study. Any substantial amendment to the protocol will be submitted to the sponsor and sent to the ethics committee for approval before implementation.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to thank all participants in the SéroPRIM study. We thank the CEPH-Biobank staff for the quality of their work. We thank also the Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation for the CEPH-Biobank funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Kurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [CrossRef] [PubMed]
2. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2020, 384, 403–416. [CrossRef] [PubMed]
3. Sadoff, J.; Gray, G.; Vandeboesch, A.; Cárdenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021, 384, 2187–2201. [CrossRef] [PubMed]
4. Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111. [CrossRef]
5. Haute Autorité de Santé. Stratégie de Vaccination Contre le SARS-CoV-2—Vaccination des Personnes Ayant un Antécédent de COVID-19. 2021. Available online: https://www.has-sante.fr/jcms/p_3237355/fr/strategie-de-vaccination-contre-le-sars-cov-2-vaccination-des-personnes-ayant-un-antecedent-de-covid-19-synthese (accessed on 2 March 2022).
6. Haute Autorité de Santé. Décision n° 2021.0139/DC/SEESP du 31 Mai 2021 du Collège de la Haute Autorité de Santé Complétant les Recommandations du 11 Février 2021 relatives à «la Vaccination des Personnes Ayant un Antécédent de COVID-19». 2021. Available online: https://www.has-sante.fr/jcms/p_3269858/fr/decision-n2021-0139/dc-seesp-du-31-mai-2021-du-college-de-la-ha-completant-les-reco-du-11-fevrier-2021-relatives-a-la-vaccination-des-personnes-ayant-un-antecedent-de-covid-19 (accessed on 2 March 2022).
7. Regev-Yochay, G.; Amit, S.; Bergwerk, M.; Lipsitch, M.; Leshem, E.; Kahn, R.; Lustig, Y.; Cohen, C.; Doolman, R.; Ziv, A.; et al. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg. Health 2021, 7, 100150. [CrossRef]
8. Levine-Tiefenbrun, M.; Yelin, I.; Alapi, H.; Katz, R.; Herzel, E.; Kuint, J.; Chodick, G.; Gazit, S.; Patalon, T.; Kishony, R. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat. Med. 2021, 27, 2108–2110. [CrossRef]
9. Yewdell, J.W. Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread. PLoS Pathog. 2021, 17, e1009509. [CrossRef]
10. Vaccines and Related Biological Products Advisory Committee Briefing Document Meeting Date: 17 September 2021; VRBPAC: Silver Spring, MD, USA, 2021. Available online: https://www.fda.gov/media/152161/download (accessed on 14 March 2022).
11. Santé Publique France. Coronavirus: Circulation des Variantes du SARS-CoV-2. 2022. Available online: https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-des-variantes-du-sars-cov-2#block-331390 (accessed on 14 March 2022).

12. Dolscheid-Pommerich, R.; Bartok, E.; Renn, M.; Kümmener, B.M.; Schulte, B.; Schmithausen, R.M.; Stoffel-Wagner, B.; Streeck, H.; Saschenbrecker, S.; Steinhagen, K.; et al. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J. Med. Virol. 2022, 94, 388-392. [CrossRef]

13. Pouquet, M.; Decarreaux, D.; Prévost-Monsacré, P.; Hervé, C.; Werner, A.; Grosgeoge, B.; Blanché, H.; Rabiega, P.; Laupie, J.; Kochert, F.; et al. Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months After the Initiation of the COVID-19 Vaccination Campaign in France. SerofPRIM Study Protocol. Pathogens 2021, 10, 911. [CrossRef] [PubMed]

14. Wei, J.; Pouvels, K.B.; Stoesser, N.; Matthews, P.C.; Diamond, I.; Studley, R.; Rourke, E.; Cook, D.; Bell, J.I.; Newton, J.N.; et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 2022, 27, 1205-1211. [CrossRef]

15. Rivett, L.; Sridhar, S.; Sparkes, D.; Routledge, M.; Jones, N.K.; Forrest, S.; Young, J.; Pereira-Dias, J.; Hamilton, W.L.; Ferris, M.; et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. eLife 2020, 9, e58728. [CrossRef] [PubMed]

16. Pouquet, M.; Decarreaux, D.; Prévost-Monsacré, P.; Hervé, C.; Werner, A.; Grosgeoge, B.; Blanché, H.; Rabiega, P.; Laupie, J.; Kochert, F.; et al. Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months After the Initiation of the COVID-19 Vaccination Campaign in France. SerofPRIM Study Protocol. Pathogens 2021, 10, 911. [CrossRef] [PubMed]

17. Patel, E.U.; Bloch, E.M.; Clarke, W.; Hsieh, Y.H.; Boon, D.; Eby, Y.; Fernandez, R.E.; Baker, O.R.; Keruly, M.; Kirby, C.S.; et al. Comparative Performance of Five Commercially Available Serologic Assays to Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titors. J. Clin. Microbiol. 2021, 59, e02257-20. [CrossRef] [PubMed]

18. Gallian, P.; Pastirino, B.; Morel, P.; Chiarioni, J.; Ninove, L.; de Lamballerie, X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antivir. Res. 2020, 181, 104880. [CrossRef]

19. Haute Autorité de Santé. Avis n° 2021.0069/AC/SESPEV du 23 Septembre 2021 du Collège de la Haute Autorité de Santé Venant Compléter l’Avis du 23 août 2021 Relatif à la Définition des Populations à Cibler par la Campagne de Rappel Vaccinal Chez les Personnes Ayant eu une Primovaccination Complète contre la COVID-19. 2021. Available online: https://www.has-sante.fr/jcms/p_3288596/fr/avis-n-2021-0069/acsespev-du-23-septembre-2021-du-collège-de-la-haute-autorité-de-sante-venant-compléter-l'avis-du-23-aout-2021-relatif-a-la-definition-des-populations-a-cibler-par-la-campagne-de-rappel-vaccinal-chez-les-personnes-ayant-eu-une-primovaccination-complete-contre-la-covid-19 (accessed on 2 March 2022).

20. Clopper, C.J.; Pearson, E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26, 404-413. [CrossRef]

21. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2006. Available online: https://www.rrccaeeuropa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/rrcdevelopment-core-team-2006 (accessed on 3 March 2022).

22. Saadat, S.; Rikhtegaran Tehrani, Z.; Logue, J.; Newman, M.; Frieman, M.B.; Harris, A.D.; Sajadi, M.M. Binding and Neutralization Antibody Titters after a Single Vaccine Dose in Health Care Workers Previously Infected with SARS-CoV-2. JAMA 2021, 325, 1467-1469. [CrossRef]

23. Moncunill, G.; Aguilar, R.; Ribes, M.; Ortega, N.; Rubio, R.; Salmerón, G.; Molina, M.J.; Vidal, M.; Barrios, D.; Mitchell, R.A.; et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. eBioMedicine 2022, 75, 103805. [CrossRef]

24. Ward, H.; Whitaker, M.; Flower, B.; Tang, S.N.; Aitchison, C.; Darzi, A.; Donnelly, C.A.; Cann, A.; Diggle, P.J.; Ashby, D.; et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 2022, 13, 907. [CrossRef]

25. Havervall, S.; Marking, U.; Greilert-Norin, N.; Gordon, M.; Ng, H.; Christ, W.; Phillipson, M.; Nilsson, P.; Hober, S.; Blom, K.; et al. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. Clin. Transl. Immunol. 2022, 11, e1388. [CrossRef]

26. Krammer, F.; Srivastava, K.; Alshammary, H.; Amoako, A.A.; Awawda, M.H.; Beach, K.F.; Bermúdez-González, M.C.; Bielak, D.A.; Carreño, J.M.; Chernet, R.L.; et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N. Engl. J. Med. 2021, 384, 1372-1374. [CrossRef]

27. Perkman, T.; Perkman-Nagle, N.; Koller, T.; Mucher, P.; Radakovic, A.; Marculescu, R.; Wolzt, M.; Wagner, O.F.; Binder, C.J.; Haslacher, H. Anti-Spike Protein Antibody Assays to Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five Quantitative Assays. Microbiol. Spectr. 2021, 9, e0024721. [CrossRef] [PubMed]

28. Ontañón, J.; Blas, J.; de Cabo, C.; Santos, C.; Ruiz-Escibano, E.; García, A.; Marín, L.; Sáez, L.; Beato, J.L.; Rada, R.; et al. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response. eBioMedicine 2021, 73, 103656. [CrossRef] [PubMed]

29. Rudberg, A.-S.; Havervall, S.; Månberg, A.; Jernbom Falk, A.; Aguilera, K.; Ng, H.; Gabrielson, L.; Salomonsson, A.-C.; Hanke, L.; Murrell, B.; et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat. Commun. 2020, 11, 5064. [CrossRef] [PubMed]
30. Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. *N. Engl. J. Med.* 2021, 385, e84. [CrossRef] [PubMed]

31. Ivanova, E.N.; Devlin, J.C.; Buus, T.B.; Koide, A.; Shwetar, J.; Cornelius, A.; Samanovic, M.J.; Herrera, A.; Mimitou, E.P.; Zhang, C.; et al. SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19. *medRxiv* 2021. [CrossRef]

32. Dagan, N.; Barda, N.; Kepten, E.; Miron, O.; Perchik, S.; Katz, M.A.; Hernán, M.A.; Lipsitch, M.; Reis, B.; Balicer, R.D. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. *N. Engl. J. Med.* 2021, 384, 1412–1423. [CrossRef]

33. Chodick, G.; Tene, L.; Rotem, R.S.; Patalon, T.; Gazit, S.; Ben-Toy, A.; Weil, C.; Goldshtein, I.; Twig, G.; Cohen, D.; et al. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data. *Clin. Infect. Dis.* 2022, 74, 472–478. [CrossRef]

34. Vicenti, I.; Gatti, F.; Scaggsiante, R.; Boccuto, A.; Zago, D.; Basso, M.; Dragoni, F.; Parisi, S.G.; Zazzi, M. The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. *Infection* 2022, 50, 541–543. [CrossRef]

35. Shrotri, M.; Fragaszy, E.; Geismar, C.; Nguyen, V.; Beale, S.; Braithwaite, I.; Byrne, T.E.; Fong, W.L.E.; Kovar, J.; Navaratnam, A.M.D.; et al. Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study). *medRxiv* 2021. [CrossRef]

36. Seow, J.; Graham, C.; Merrick, B.; Acors, S.; Pickering, S.; Steel, K.J.A.; Hemmings, O.; O’Byrne, A.; Koupouh, N.; Galao, R.P.; et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat. Microbiol.* 2020, 5, 1598–1607. [CrossRef]

37. Mizrahi, B.; Lotan, R.; Kalkstein, N.; Benz, A.; Perez, G.; Ben-Toy, A.; Chodick, G.; Gazit, S.; Patalon, T. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. *Nat. Commun.* 2021, 12, 6379. [CrossRef] [PubMed]

38. Jo, D.H.; Minn, D.; Lim, J.; Lee, K.D.; Kang, Y.M.; Choe, K.W.; Kim, K.-N. Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination. *Vaccines* 2021, 9, 1145. [CrossRef] [PubMed]

40. Ong, S.W.X.; Chiew, C.J.; Ang, L.W.; Mak, T.M.; Cui, L.; Toh, M.; Lim, Y.D.; Lee, P.H.; Lee, T.H.; Chia, F.Y.; et al. Clinical and virological features of SARS-CoV-2 variants of concern: A retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). *Clin. Infect. Dis.* 2021; in press. [CrossRef] [PubMed]

41. Feng, S.; Phillips, D.; White, T.; Sayal, H.; Aley, P.; Bibi, S.; Dold, C.; Fuskova, M.; Gilbert, S.C.; Hirsch, I.; et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *medRxiv* 2021. [CrossRef]

42. Dobaño, C.; Santano, R.; Jimenez, A.; Vidal, M.; Chi, J.; Rodrigo Meiero, N.; Popovic, M.; Lopez-Aladid, R.; Fernández-Barat, L.; Tortajada, M.; et al. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: Utility and limitations in seroprevalence and immunity studies. *Transl. Res.* 2021, 232, 60–74. [CrossRef]

43. Lozano-Ojalvo, D.; Camara, C.; Lopez-Granados, E.; Nozal, P.; Del Pino-Molina, L.; Bravo-Gallego, L.Y.; Paz-Artal, E.; Pion, M.; Correa-Rocha, R.; Ortiz, A.; et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. *Cell Rep.* 2021, 36, 109570. [CrossRef]

44. Krutikov, M.; Palmer, T.; Tut, G.; Fuller, C.; Azmi, B.; Giddings, R.; Shrotri, M.; Kaur, N.; Sylla, P.; Lancaster, T.; et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): Prospective cohort study in England. *Lancet Healthy Longev.* 2022, 3, e13–e21. [CrossRef]